 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 220
Date: March 6, 2024
Biogen Idec, the folks that brought us Rituxan, are busy developing a new monoclonal antibody for use in CLL.
Lumiliximab (I far prefer the shorter and sexier name “Lumi”) is the latest monoclonal antibody and it has some interesting features that might make it useful in treating CLL. It targets CD23, a marker which is brightly expressed by CLL cells and is in fact a B-cell activation marker. This new monoclonal antibody appears to have an enviably low toxicity profile.
In our latest article Lumiliximab: The Next Drug in CLL? we give you the inside scoop on Lumi, the inevitable risks-versus-rewards comparison, and evaluate the newly launched pivotal Phase III multi-center clinical trial which compares FCR + Lumi with the standard FCR therapy regime. This trail might be interesting to our readers who are thinking of starting FCR therapy. Half the patients will get FCR, while the other half will get a chance at the potentially more effective combination of FCR + Lumi. There are trial centers recruiting in the US, Canada, Australia and Europe. You can check out all the details in our review.
As always, your feedback is important to us. Do let us know if you decide to go ahead and participate in this clinical trial.
Be well,
Chaya
_____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
